Patent ID: 7026289
Filing Date: 2006-04-11
Classification: A61K,A61P

Abstract:
1. A pharmaceutical composition for the treatment of hyperlipidemia in a patient in need thereof, comprising a therapeutically effective amount of an agonist selective for the somatostatin type-5 receptor and having a higher binding affinity for the somatostatin type-5 receptor than for either the somatostatin type-1, type-2, type-3 or type-4 receptor and a binding affinity (Ki) of less than 5 nM for the somatostatin type-5 receptor, wherein said agonist is selected from the group consisting of H-Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys-NH 2 ; H-Cys-Phe-Phe-D-Trp-Lys-Ser-Phe-Cys-NH 2 ; H-Cys-Phe-Tyr-D-Trp-Lys-Thr-Phe-Cys-NH 2 ; H-Cys-Phe-Tyr(I)-D-Trp-Lys-Thr-Phe-Cys-NH 2 ; and and wherein said therapeutically effective amount is an amount that is effective for the treatment of hyperlipidemia in said patient.